Review article: drug‐induced liver injury in clinical practice

Bjõrnsson, Einar

doi:10.1111/j.1365-2036.2010.04320.x

Cited by 132 publications

(86 citation statements)

References 91 publications

(407 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The phenomenon of transaminase normalisation despite continuation of a treatment has been called adaptation [43]. It involves genes of drug metabolizing enzymes and transporters.…”

Section: Discussionmentioning

confidence: 99%

Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients

et al. 2016

View full text Add to dashboard Cite

Authorship statementGP, PC, DV, DG, KM have analyzed all the suspected cases of liver injury.GP wrote the manuscript.PC, DV, DG, BS, KM corrected the manuscript.BS and CB performed the statistical analyses.Perlemuter G et al. Agomelatine and liver injury 3 ABSTRACT Background. Antidepressant-induced liver injury is a major concern and a liver monitoring scheme has been recommended by the European Medicine Agency for agomelatine.Objective. To assess the liver safety and identify the characteristics of patients who developed a significant increase in transaminases whilst taking agomaatine. Method.A retrospective pooled analysis of changes in transaminase levels in 9,234 patients treated with agomelatine (25mg or 50mg/day; n=7,605) or placebo (n=1,629) from 49 phase II and III studies was undertaken. A significant increase in transaminase levels was defined as an increase to >3-fold the upper limit of normal (>3ULN). Final causality was determined in a case-by-case review by five academic experts. -Withdrawal of agomelatine leads to rapid recovery.-Some patients exhibit an adaptative phenomenon.-The liver profile of agomelatine seems safe when serum transaminases are monitored.Perlemuter G et al. Agomelatine and liver injury 5

show abstract

“…The phenomenon of transaminase normalisation despite continuation of a treatment has been called adaptation [43]. It involves genes of drug metabolizing enzymes and transporters.…”

Section: Discussionmentioning

confidence: 99%

Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Although the risk of liver damage related to NSAID use is thought to be rare, several reviews have identified NSAIDs as the most common drugs to cause liver injury. 32,[84][85][86][87][88][89][90] The estimated incidence of NSAID-associated hepatotoxicity is between 3 and 23 per 100,000 patientyears. 87 Risk factors for NSAID-induced hepatotoxicity include P = 0.025 for ibuprofen Table 2).…”

Section: 78mentioning

confidence: 99%

NSAIDs for Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety

Atchison¹,

Herndon²,

Rusie³

2013

JMCP

View full text Add to dashboard Cite

and completed residency training in physical medicine and rehabilitation at The Ohio State University. Dr. Atchison has been in practice at academic medical centers for more than 20 years, serving on the faculty at the University of Kentucky and University of Florida before his appointment at Northwestern University. A recognized teacher and researcher in the field of pain management and rehabilitation, he has presented courses, lectures, and workshops nationally and internationally on pharmacological and nonpharmacological therapies, care of spinal injuries, and spinal manipulation. Dr. Atchison has led and participated in many research projects, including several funded by the National Institutes of Health. He has authored numerous research papers and book chapters, and he serves as a peer reviewer for the Archives of Physical Medicine and Rehabilitation. He has been a member of the editorial boards of the Supplement Policy Statement Standards for Supplements to the Journal of Managed Care PharmacySupplements to the Journal of Managed Care Pharmacy are intended to support medical education and research in areas of clinical practice, health care quality improvement, or efficient administration and delivery of health benefits. The following standards are applied to all JMCP supplements to ensure quality and assist readers in evaluating potential bias and determining alternate explanations for findings and results. 1. Disclose the principal sources of funding in a manner that permits easy recognition by the reader. 2. Disclose the existence of all potential conflicts of interest among supplement contributors, including financial or personal bias. 3. Describe all drugs by generic name unless the use of the brand name is necessary to reduce the opportunity for confusion among readers. 4. Identify any off-label (unapproved) use by drug name and specific off-label indication. 5. Strive to report subjects of current interest to managed care pharmacists and other managed care professionals. S14 Multitarget Drugs S15 Conclusions S15 References Target AudiencesThis CME/CE activity is designed to meet the educational needs of pharmacists, physicians, nurse practitioners, and nurses. Learning Objectives• Assess patient-specific risk factors in selecting NSAIDs for mild-to-moderate musculoskeletal pain • Incorporate risk/benefit analysis in decision making about NSAID use • Use evidence-based guidelines for selecting NSAID therapy and applying strategies to prevent complications • Evaluate the efficacy, safety, and pharmacological profile of new and emerging NSAID formulations Funding This supplement was funded by an independent educational grant to PRIME Education, Inc. (PRIME) from Iroko Pharmaceuticals, LLC. Accreditation StatementsIn support of improving patient care, PRIME Education, Inc. (PRIME) is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing educat...

show abstract

“…Drug induced liver injury (DILI) occurs roughly between 1-2 weeks from start of drug therapy and presents with acute liver failure and hepatic encephalopathy. 4 Drug induced TEN and Drug induced liver injury (DILI) occurring in association is rarely reported. There are very few case reports of association between piperacillintazobactam and TEN.…”

Section: Discussionmentioning

confidence: 99%

Piperacillin/tazobactam induced toxic epidermal necrolysis and drug induced liver injury

et al. 2018

View full text Add to dashboard Cite

The liver and skin are the organs most commonly involved in serious adverse drug reactions. Rarely a drug reaction can affect both organs concurrently. The association of drug induced liver injury (DILI) and toxic epidermal necrolysis (TEN) is even rarer and may be rarely reported. This is a case report on development of both TEN and DILI following use of piperacillin / tazobactam. We describe our experience of DILI occurring in association with TEN including the etiological agent responsible, its clinical/ biochemical characteristics and ultimate outcome.

show abstract

Review article: drug‐induced liver injury in clinical practice

Abstract: SUMMARY BackgroundDrug-induced liver injury (DILI) is an important differential diagnosis in many patients in clinical hepatology. DILI is the leading cause of acute liver failure and is an important safety issue when new drugs are developed.

Cited by 132 publications

References 91 publications

Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients

Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients

NSAIDs for Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety

Piperacillin/tazobactam induced toxic epidermal necrolysis and drug induced liver injury

Contact Info

Product

Resources

About